Myocardial Infarction News and Research

RSS

OrbusNeich commences enrollment in Chinese Genous Bio-engineered R stent trial

OrbusNeich today announced that the first patient has been enrolled in a randomized clinical trial of the Genous Bio-engineered R stent in China.

12 Feb 2010

Concomitant use of dexlansoprazole and other PPIs with Plavix: TGRD U.S. initiates trial

Takeda Global Research & Development Center, Inc., U.S., (TGRD U.S.) announced today that it has initiated a trial to study how dexlansoprazole and several other proton pump inhibitors (PPIs) affect the pharmacokinetics and pharmacodynamics of Plavix (clopidogrel bisulfate) in healthy subjects. Takeda has been evaluating all published data and communications from the U.S. Food and Drug Administration (FDA) regarding the potential risks associated with concomitant use of clopidogrel and PPIs.

10 Feb 2010

Volcano acquires Xtract Thrombus Aspiration Catheter device from Lumen Biomedical

Volcano Corporation, a leading developer and manufacturer of precision intravascular therapy guidance tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, announced today that it has acquired the Xtract™ Thrombus Aspiration Catheter device line from Lumen Biomedical.

9 Feb 2010

Risk of heart attack greater in women with gout

Women with gout are at greater risk of a heart attack than men with the disease, indicates research published ahead of print in the Annals of the Rheumatic Diseases.

7 Feb 2010

EuroHOPE study: Performance evaluation of the European healthcare system

The performance of the European healthcare system will be evaluated in the EuroHOPE study (European Health Care Outcomes, Performance and Effectiveness) coordinated by the Finnish National Institute for Health and Welfare (THL) and funded by the EU.

6 Feb 2010

HUCB-derived purified and expanded CD133+ cells may show promise in cellular cardiomyoplasty

Researchers at the Pontif-cia Universidade Cat-lica do Paran- and Instituto Carlos Chagas have evaluated the therapeutic potential of purified and expanded CD133+ cells human umbilical cord blood (HUCB)-derived in treating myocardial infarction by intramyocardially injecting them into a rat model. Patients who have high cardiovascular risks have fewer endothelial progenitor cells (EPCs) and their EPCs exhibit greater in vitro senescence.

4 Feb 2010

Smoking cessation increases cardiac health later in life

Smoking affects your cardiac health both before and after a major event like a heart attack. But how much? And does cutting back instead of quitting have a positive effect as well?

2 Feb 2010

Research roundup: Raising seniors' co-pays increases costs; The stimulus and safety net providers

New England Journal of Medicine: Increased Ambulatory Care Copayments And Hospitalizations Among The Elderly - This study examines the consequences of increasing copayments for outpatient care of Medicare enrollees in managed-care plans. "As compared with matched control plans in which copayments for ambulatory care were unchanged, Medicare plans that increased these copayments by an average of 95% for primary care and 74% for specialty care had a reduction in the number of outpatient visits but an increase in hospital admissions, in the number of days of hospital care, and in the proportion of enrollees who used hospital care," the authors write.

30 Jan 2010

Life Technologies collaborates with Ignite Institute to create genomic sequencing center

Life Technologies Corporation and the Ignite Institute for Individualized Health announced today a collaboration to create a ground-breaking genomic sequencing center at Ignite’s new facility in Northern Virginia.

28 Jan 2010

Depression raises risks of advanced and severe complications from diabetes

Depression raises risks of advanced and severe complications from diabetes, according to a prospective study of Group Health primary-care patients in western Washington. These complications include kidney failure or blindness, the result of small vessel damage, as well as major vessel problems leading to heart attack or stroke.

28 Jan 2010

Thoratec expands MCS portfolio with innovative catheter pump technology

Thoratec Corporation, a world leader in device-based mechanical circulatory support (MCS) therapies to save, support and restore failing hearts, said today that it has acquired an innovative catheter pump technology that it plans to use in the development of a minimally invasive, acute cardiac axial flow pump that can be delivered percutaneously in the cardiac catheterization lab and operating room.

27 Jan 2010

OrbusNeich's clinical data demonstrates the benefits of Genous Bio-engineered R stent

OrbusNeich announced that clinical data presented today at Asia PCR/Singapore LIVE 2010 demonstrated the benefits of the Genous Bio-engineered R stent in the treatment of two challenging patient subsets.

24 Jan 2010

UK Gill Heart Institute offers individualized fitness program for heart patients

How do you change health habits among a population with some of the highest heart disease rates in the world? Tackling heart disease in Kentucky - an epicenter of heart health problems - the University of Kentucky Gill Heart Institute Cardiac Rehabilitation Program is helping high-risk patients make radical, lasting changes to improve their heart health.

23 Jan 2010

Outcomes for STEMI patients improve with early treatment intervention

A recent study found that individuals experiencing chest pain who had electrocardiogram (ECG or EKG) assessments prior to arriving at the hospital experienced a significantly reduced time-to-treatment or door-to-balloon (D2B) time.

21 Jan 2010

LUMEN 2010 analyzes strategies to reduce rising mortality in women with cardiovascular disease

It is no longer a theory. Percutaneous coronary intervention (PCI) or coronary angioplasty is the best treatment for a person presenting with STEMI (ST- elevation myocardial infarction), a heart attack caused by complete obstruction of a coronary artery.

13 Jan 2010

European Society of Cardiology warns public about risk factors involved in obesity, diabetes and hypertension

Following the sudden death yesterday of the former French government minister Philippe Séguin, who suffered a fatal heart attack, aged 66, the European Society of Cardiology is warning the public of the dangers of leaving risk factors such as hyperlipidemia, hypertension or diabetes untreated. Other major risk factors for coronary artery disease are smoking or being overweight.

9 Jan 2010

Japanese MHLW approves Abbott's XIENCE V Everolimus Eluting Coronary Stent System

Abbott announced today that the Japanese Ministry of Health, Labor and Welfare (MHLW) has approved its XIENCE V® Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease.

8 Jan 2010

MicroCHIPS raises $16.5 million to fund for diabetes and osteoporosis programs

MicroCHIPS, Inc., a developer of intelligent implant systems, has raised $16.5 million to fund its lead programs in diabetes and osteoporosis. Current investors Polaris Venture Partners, Novartis Venture Fund, Flybridge Capital Partners, Medtronic, Saints Capital, Intersouth Partners, Care Capital and CSK Venture Capital were joined by new investor InterWest Partners.

8 Jan 2010

Boston Scientific commences enrollment in its TAXUS Liberte Stent System study

Boston Scientific Corporation today announced that it has enrolled the first patient in its TAXUS Liberte post-approval study. The study is designed to evaluate real-world clinical outcomes data for the TAXUS® Liberte® Paclitaxel-Eluting Coronary Stent System in combination with a dual antiplatelet therapy drug regimen that includes aspirin and Effient®, a new antiplatelet medication. Co-sponsors of the study include Eli Lilly and Company and Daiichi Sankyo, Inc., manufacturers of Effient, which was recently approved by the U.S. Food and Drug Administration (FDA).

4 Jan 2010

FDA approves distribution of ZOLL E Series Monitor/Defibrillator

ZOLL Medical Corporation, a manufacturer of resuscitation devices and related software solutions, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for a new model of the ZOLL E Series® Monitor/Defibrillator with carbon monoxide (CO) measurement. The product is immediately available for shipment.

31 Dec 2009